The pipeline
49 programmes in development for hair loss and hair regeneration. Sorted by phase, latest first.
49 programmes
| Programme | Developer | Phase | Approach | Mechanism | Last activity |
|---|---|---|---|---|---|
| Minoxidil (low-dose oral) High· 4 trials | Unknown | Marketed, off-label | Oral | Potassium channel opener | 3 months ago |
| Baricitinib (Olumiant) High· 7 trials | Eli Lilly | Approved | Oral | JAK inhibitor | 1 month ago |
| Deuruxolitinib (Leqselvi) High· 10 trials | Sun Pharmaceutical | Approved | Oral | JAK inhibitor | 1 month ago |
| Dutasteride (Avodart / Zagallo) High· 9 trials | GSK | Approved | Oral | 5α-reductase inhibitor | 4 months ago |
| Finasteride (Propecia) High· 5 trials | Organon | Approved | Oral | 5α-reductase inhibitor | 8 months ago |
| Minoxidil (topical) High· 38 trials | Unknown | Approved | Topical | Potassium channel opener | 1 month ago |
| Ritlecitinib (Litfulo) High· 15 trials | Pfizer | Approved | Oral | JAK inhibitor | 1 month ago |
| Topical finasteride High· 3 trials | Almirall | Approved | Topical | 5α-reductase inhibitor | No public activity in over 18 months |
| Upadacitinib (Rinvoq) High· 4 trials | AbbVie | Approved | Oral | JAK inhibitor | 1 month ago |
| Coacillium (LH-8) High | Legacy Healthcare | Filed with regulator | Topical | Other | Never |
| Ivarmacitinib (ARQ-252) Medium· 2 trials | Unknown | Filed with regulator | Oral | JAK inhibitor | No public activity in over 18 months |
| AD-208 Low· 2 trials | Addpharma | Phase 3 | Oral | Undisclosed | No public activity in over 18 months |
| BL 3000 Low· 1 trials | Biolab Sanus Farmacêutica | Phase 3 | Oral | Undisclosed | No public activity in over 18 months |
| CKD-843 Medium· 3 trials | Chong Kun Dang Pharmaceutical | Phase 3 | Injectable | 5α-reductase inhibitor | 16 months ago |
| Clascoterone (Breezula) High· 2 trials | Cosmo Pharmaceuticals | Phase 3 | Topical | Androgen receptor | 2 months ago |
| DA-001 / DA-002 / DA-005 Medium· 6 trials | Applied Biology | Phase 3 | Topical | Adrenergic | 4 months ago |
| Eniagor Low· 1 trials | Apsen Farmacêutica | Phase 3 | Other | Combination | 4 months ago |
| Jaktinib High· 4 trials | Suzhou Zelgen Biopharmaceuticals | Phase 3 | OralTopical | JAK inhibitor | 17 months ago |
| N1087 Low· 1 trials | Eurofarma Laboratórios | Phase 3 | Other | Undisclosed | 7 months ago |
| OMA102 Low· 1 trials | EMS | Phase 3 | Other | Undisclosed | No public activity in over 18 months |
| Pyrilutamide High· 7 trials | Kintor Pharmaceutical | Phase 3 | Topical | Androgen receptor | No public activity in over 18 months |
| TH07 Low· 1 trials | Triple Hair | Phase 3 | Topical | Undisclosed | 5 months ago |
| VDPHL-01 (oral minoxidil) Medium· 4 trials | Veradermics | Phase 3 | Oral | Potassium channel opener | 1 month ago |
| Dalosirvat (SM-04554) Medium· 3 trials | Biosplice Therapeutics | Phase 2/3 | Topical | Wnt pathway | No public activity in over 18 months |
| Amlitelimab High· 1 trials | Sanofi | Phase 2 | BiologicInjectable | Immunomodulator | 1 month ago |
| ASLAN003 Low· 1 trials | ASLAN Pharmaceuticals | Phase 2 | Oral | Undisclosed | No public activity in over 18 months |
| BNZ-1 Medium· 1 trials | Equillium | Phase 2 | BiologicInjectable | Immunomodulator | No public activity in over 18 months |
| Brepocitinib Medium· 2 trials | Priovant Therapeutics | Phase 2 | Oral | JAK inhibitor | 3 months ago |
| CG 428 Low· 3 trials | Legacy Healthcare | Phase 2 | Topical | Undisclosed | No public activity in over 18 months |
| CKD-498 Low· 1 trials | Chong Kun Dang Pharmaceutical | Phase 2 | Other | Undisclosed | No public activity in over 18 months |
| Daxdilimab High· 1 trials | Amgen | Phase 2 | BiologicInjectable | Immunomodulator | No public activity in over 18 months |
| Delgocitinib (LEO 124249) High· 5 trials | LEO Pharma | Phase 2 | Topical | JAK inhibitor | 1 month ago |
| Deucravacitinib High· 2 trials | Bristol Myers Squibb | Phase 2 | Oral | JAK inhibitor | 1 month ago |
| Etrasimod Medium· 1 trials | Pfizer | Phase 2 | Oral | Immunomodulator | No public activity in over 18 months |
| GT20029 Medium· 3 trials | Kintor Pharmaceutical | Phase 2 | Topical | Androgen receptor | No public activity in over 18 months |
| HMI-115 Medium· 2 trials | Hope Medicine | Phase 2 | InjectableBiologic | Prolactin receptor | 14 months ago |
| PP405 High· 1 trials | Pelage Pharmaceuticals | Phase 2 | Topical | Metabolic / mitochondrial | 8 months ago |
| Rosnilimab High· 1 trials | AnaptysBio | Phase 2 | BiologicInjectable | Immunomodulator | No public activity in over 18 months |
| SYHX1901 Low· 1 trials | CSPC Pharmaceutical Group | Phase 2 | Other | Undisclosed | 14 months ago |
| TDM-105795 Medium· 4 trials | TechnoDerma Medicines | Phase 2 | Topical | Thyroid hormone receptor | 9 months ago |
| VC005 Low· 2 trials | Jiangsu Vcare Pharmaceutical | Phase 2 | Oral | Undisclosed | 1 month ago |
| DLQ-01 (latanoprost) Medium· 1 trials | DermaLiq Therapeutics | Phase 1/2 | Topical | Prostaglandin | No public activity in over 18 months |
| Epibiotech dermal papilla cell therapy Medium· 1 trials | Epibiotech | Phase 1/2 | Cell therapyInjectable | Stem cell activation | 2 months ago |
| AMP-303 Medium | Amplifica | Phase 1 | Injectable | Signalling peptide | Never |
| ET-02 Medium | Eirion Therapeutics | Phase 1 | Topical | Stem cell activation | Never |
| HairClone follicle banking & cell therapy Medium | HairClone | Phase 1 | Cell therapy | Stem cell activation | Never |
| ANR-001.1 (latanoprost + minoxidil) Low | Aneira Pharma | Phase 0 | Topical | Combination | Never |
| OrganTech / Tsuji follicular primordium Low | OrganTech | Preclinical | Hair cloning & follicle neogenesis | Stem cell activation | Never |
| TissUse Smart Hair Transplant Low | TissUse | Preclinical | Hair cloning & follicle neogenesisSurgical | Stem cell activation | Never |